Yield10 Bioscience, Inc.

OTCPK:YTEN.Q Stock Report

Market Cap: US$1.5k

Yield10 Bioscience Management

Management criteria checks 3/4

Yield10 Bioscience's CEO is Olly Peoples, appointed in Oct 2016, has a tenure of 8.25 years. total yearly compensation is $598.55K, comprised of 57.5% salary and 42.5% bonuses, including company stock and options. directly owns 2.85% of the company’s shares, worth $41.77. The average tenure of the management team and the board of directors is 8.3 years and 18.3 years respectively.

Key information

Olly Peoples

Chief executive officer

US$598.6k

Total compensation

CEO salary percentage57.5%
CEO tenure8.3yrs
CEO ownership2.8%
Management average tenure8.3yrs
Board average tenure18.3yrs

Recent management updates

Recent updates

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Aug 10

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Nov 12
Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Jul 19
Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 18
Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Apr 14
Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Yield10 Bio secures $12.7M capital raise

Feb 01

Yield10 Bioscience under pressure on launching stock offering

Jan 29

When Will Yield10 Bioscience, Inc. (NASDAQ:YTEN) Become Profitable?

Jan 22
When Will Yield10 Bioscience, Inc. (NASDAQ:YTEN) Become Profitable?

CEO Compensation Analysis

How has Olly Peoples's remuneration changed compared to Yield10 Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$13m

Dec 31 2023US$599kUS$344k

-US$14m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$527kUS$331k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$12m

Dec 31 2021US$2mUS$315k

-US$11m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$1mUS$289k

-US$10m

Sep 30 2020n/an/a

-US$14m

Jun 30 2020n/an/a

-US$14m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$600kUS$275k

-US$13m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$9m

Dec 31 2018US$738kUS$275k

-US$9m

Compensation vs Market: Olly's total compensation ($USD598.55K) is about average for companies of similar size in the US market ($USD642.50K).

Compensation vs Earnings: Olly's compensation has increased whilst the company is unprofitable.

CEO

Olly Peoples (66 yo)

8.3yrs

Tenure

US$598,554

Compensation

Dr. Oliver P. Peoples, also known as Olly, Ph D., is a Co-founder of Metabolix Inc., and has been its Chief Executive Officer and President since October 17, 2016. Dr. Peoples served as its Chief Scientifi...

Leadership Team

NamePositionTenureCompensationOwnership
Oliver Peoples
Co-Founder8.3yrsUS$598.55k2.85%
$ 41.8
Lynne Brum
VP of Planning & Corporate Communications and Secretary8.3yrsUS$366.98k1.71%
$ 25.1
Charles Haaser
VP of Finance10.2yrsUS$251.94k0.82%
$ 12.0

8.3yrs

Average Tenure

66yo

Average Age

Experienced Management: YTEN.Q's management team is seasoned and experienced (8.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Oliver Peoples
Co-Founder32.6yrsUS$598.55k2.85%
$ 41.8
Richard Hamilton
Independent Director7.8yrsUS$74.84k0.41%
$ 6.0
Robert Van Nostrand
Independent Chairman of the Board18.3yrsUS$84.84k0.28%
$ 4.1

18.3yrs

Average Tenure

66yo

Average Age

Experienced Board: YTEN.Q's board of directors are seasoned and experienced ( 18.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 15:09
End of Day Share Price 2025/01/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yield10 Bioscience, Inc. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Han JangAegis Capital Corporation
Jinming LiuArdour Capital Investments, LLC
Benjamin KlieveB. Riley Wealth